Avecho Biotechnology Limited logo

Avecho Biotechnology Limited (OEZ)

Market Open
12 Dec, 20:00
XSTU XSTU
0. 00
0
0%
- Market Cap
- P/E Ratio
0.67% Div Yield
0 Volume
0 Eps
0
Previous Close
Day Range
0 0
Year Range
0 0.01
Want to track OEZ and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 44 days

Summary

OEZ trading today higher at €0, an increase of 0% from yesterday's close, completing a monthly increase of 0% or €0. Over the past 12 months, OEZ stock gained 600%.
OEZ pays dividends to its shareholders, with the most recent payment made on Oct 21, 2010. The next estimated payment will be in 21 Oct 2010 on Oct 21, 2010 for a total of €0.03.
The last earnings report, released on Aug 25, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Jan 28, 2026.
The stock of the company had never split.
The company's stock is traded on 5 different exchanges and in various currencies, with the primary listing on ASX (AUD).

OEZ Chart

Avecho Biotechnology Limited (OEZ) FAQ

What is the stock price today?

The current price is €0.00.

On which exchange is it traded?

Avecho Biotechnology Limited is listed on ASX.

What is its stock symbol?

The ticker symbol is OEZ.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.67%.

What is its market cap?

As of today, no market cap data is available.

When is the next earnings date?

The next earnings report will release on Jan 28, 2026.

Has Avecho Biotechnology Limited ever had a stock split?

No, there has never been a stock split.

Avecho Biotechnology Limited Profile

Biotechnology Industry
Healthcare Sector
Dr. Paul Gavin BSc (Hons), Ph.D. CEO
XSTU Exchange
AU0000047441 ISIN
AU Country
- Employees
- Last Dividend
23 Apr 1999 Last Split
- IPO Date

Overview

Avecho Biotechnology Limited is a distinguished biotechnology firm rooted in Clayton, Australia, focusing on the invention and market introduction of products beneficial for both human and animal health. Utilizing its unique drug delivery system alongside Tocopherol Phosphate Mixture (TPM), the company excels in the biotechnology sector. Established in 1992, Avecho operates across two main segments: Production and Human Health, underscoring its versatility and commitment to improving health outcomes. Through strategic collaborations, such as with the Lambert Initiative at the University of Sydney for osteoarthritis treatment, Avecho underscores its devotion to advancing medical research and delivering innovative health solutions.

Products and Services

  • TPM and Vital ET Products:
  • A cornerstone of Avecho's product lineup, TPM (Tocopherol Phosphate Mixture) and Vital ET products are designed for drug delivery and cosmetic formulations. These products leverage Avecho's proprietary delivery system to enhance the effectiveness and stability of active ingredients, offering advancements in topical and systemic therapeutics and in cosmetic applications.

  • Human Health Portfolio:
  • This portfolio features a variety of delivery mechanisms for pharmaceutical products, including gels, injectables, and patches. Aimed at improving patient outcomes and experience, these delivery systems are developed to ensure precise dosing, enhance drug absorption, and provide user-friendly applications for medications, addressing a range of health conditions.

  • Feed Additive Products:
  • With an eye on the agricultural sector, Avecho is also developing feed additive products intended to boost feed efficiency and the overall health of livestock animals. These innovations underscore the company's commitment to contributing towards sustainable livestock management by enhancing nutritional intake and promoting healthier livestock, which is vital for the agriculture industry.

Contact Information

Address: 2A Westall Road
Phone: 61 3 9002 5000